Name | Number of supported studies | Average coverage | |
---|---|---|---|
pericyte | 35 studies | 44% ± 22% | |
fibroblast | 33 studies | 34% ± 17% | |
smooth muscle cell | 32 studies | 45% ± 19% | |
endothelial cell | 30 studies | 32% ± 13% | |
endothelial cell of vascular tree | 14 studies | 36% ± 18% | |
endothelial cell of artery | 13 studies | 34% ± 15% | |
myofibroblast cell | 13 studies | 40% ± 15% | |
connective tissue cell | 11 studies | 32% ± 16% | |
vein endothelial cell | 11 studies | 32% ± 12% | |
capillary endothelial cell | 5 studies | 25% ± 9% | |
endothelial cell of lymphatic vessel | 4 studies | 19% ± 3% | |
glomerular endothelial cell | 4 studies | 34% ± 15% | |
epithelial cell | 4 studies | 32% ± 14% | |
adventitial cell | 4 studies | 31% ± 14% | |
kidney loop of Henle epithelial cell | 3 studies | 18% ± 2% | |
extravillous trophoblast | 3 studies | 34% ± 7% | |
basal cell | 3 studies | 29% ± 11% | |
secretory cell | 3 studies | 21% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 92225.49 | 180 / 180 | 90% | 45.99 | 387 / 430 |
prostate | 91% | 16639.44 | 223 / 245 | 92% | 47.84 | 462 / 502 |
breast | 99% | 27257.24 | 456 / 459 | 78% | 26.21 | 869 / 1118 |
kidney | 83% | 14352.40 | 74 / 89 | 94% | 69.30 | 843 / 901 |
lung | 98% | 23080.13 | 565 / 578 | 78% | 24.12 | 897 / 1155 |
thymus | 92% | 15735.08 | 602 / 653 | 82% | 22.95 | 498 / 605 |
bladder | 100% | 23670.48 | 21 / 21 | 65% | 20.89 | 330 / 504 |
uterus | 98% | 23263.23 | 166 / 170 | 58% | 23.84 | 265 / 459 |
esophagus | 77% | 14266.98 | 1113 / 1445 | 73% | 23.10 | 134 / 183 |
skin | 64% | 10853.79 | 1155 / 1809 | 81% | 27.91 | 380 / 472 |
adrenal gland | 66% | 7375.36 | 169 / 258 | 73% | 31.32 | 169 / 230 |
intestine | 81% | 13624.32 | 781 / 966 | 50% | 11.11 | 266 / 527 |
stomach | 67% | 12632.38 | 239 / 359 | 61% | 16.36 | 175 / 286 |
pancreas | 20% | 1870.28 | 67 / 328 | 92% | 34.47 | 164 / 178 |
blood vessel | 100% | 53549.17 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 43964.40 | 1200 / 1204 | 0% | 0 | 0 / 0 |
heart | 83% | 14718.36 | 712 / 861 | 0% | 0 | 0 / 0 |
muscle | 74% | 6991.57 | 594 / 803 | 0% | 0 | 0 / 0 |
brain | 21% | 1754.51 | 556 / 2642 | 52% | 12.36 | 367 / 705 |
liver | 30% | 2682.70 | 68 / 226 | 38% | 8.75 | 156 / 406 |
tonsil | 0% | 0 | 0 / 0 | 58% | 11.74 | 26 / 45 |
eye | 0% | 0 | 0 / 0 | 36% | 5.11 | 29 / 80 |
lymph node | 0% | 0 | 0 / 0 | 21% | 3.32 | 6 / 29 |
spleen | 14% | 958.73 | 33 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0001542 | Biological process | ovulation from ovarian follicle |
GO_0060347 | Biological process | heart trabecula formation |
GO_0030198 | Biological process | extracellular matrix organization |
GO_0001822 | Biological process | kidney development |
GO_0016525 | Biological process | negative regulation of angiogenesis |
GO_1900087 | Biological process | positive regulation of G1/S transition of mitotic cell cycle |
GO_0007229 | Biological process | integrin-mediated signaling pathway |
GO_0006508 | Biological process | proteolysis |
GO_1904707 | Biological process | positive regulation of vascular associated smooth muscle cell proliferation |
GO_1904754 | Biological process | positive regulation of vascular associated smooth muscle cell migration |
GO_0005576 | Cellular component | extracellular region |
GO_0031410 | Cellular component | cytoplasmic vesicle |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0031012 | Cellular component | extracellular matrix |
GO_0005604 | Cellular component | basement membrane |
GO_0008201 | Molecular function | heparin binding |
GO_0008237 | Molecular function | metallopeptidase activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0004222 | Molecular function | metalloendopeptidase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | ADAMTS1 |
Protein name | A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAM-TS 1) (ADAM-TS1) (ADAMTS-1) (EC 3.4.24.-) (METH-1) ADAM metallopeptidase with thrombospondin type 1 motif, 1 ADAM metallopeptidase with thrombospondin type 1 motif 1 |
Synonyms | KIAA1346 METH1 |
Description | FUNCTION: Cleaves aggrecan, a cartilage proteoglycan, at the '1938-Glu-|-Leu-1939' site (within the chondroitin sulfate attachment domain), and may be involved in its turnover (By similarity). Has angiogenic inhibitor activity. Active metalloprotease, which may be associated with various inflammatory processes as well as development of cancer cachexia. May play a critical role in follicular rupture. . |
Accessions | Q9UHI8 A0A7I2YQL5 ENST00000676955.1 E5RI60 ENST00000677958.1 ENST00000679152.1 ENST00000517777.6 Q8NE26 ENST00000451462.6 ENST00000678221.1 A0A7I2V400 A0A7I2V5J1 ENST00000284984.8 |